EX-10.1



 Exhibit 10.1 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 

EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

THIS EXCLUSIVE CHANNEL COLLABORATION
AGREEMENT (the “Agreement”) is made and entered into effective as of March 26, 2014 (the “Effective Date”) by and between INTREXON
CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and INTREXON ENERGY PARTNERS,
LLC, a Delaware limited liability company having a place of business at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“NewCo”). Intrexon and NewCo may be referred to herein individually as a “Party”, and
collectively as the “Parties.” 
 RECITALS 

WHEREAS, Intrexon has expertise in and owns or controls proprietary technology relating to the
identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression; and 

WHEREAS, NewCo now desires to become Intrexon’s exclusive channel collaborator with respect to such
technology for the purpose of developing Collaboration Products (as defined herein), and Intrexon is willing to appoint NewCo as a channel collaborator in the Field (as defined herein, and subject to amendments to the definition as permitted herein)
under the terms and conditions of this Agreement. 
 NOW THEREFORE, in consideration of
the foregoing and the covenants and promises contained herein, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 

As used in this Agreement, the following capitalized terms shall have the following meanings: 

1.1 “Affiliate” means, with respect to a particular Party, any other person or entity that directly or indirectly
controls, is controlled by, or is in common control with such Party. As used in this Section 1.1, the term “controls” (with correlative meanings for the terms “controlled by” and “under common control with”) means
the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of an entity, or the possession, directly or indirectly, of the power to direct the management or policies of an entity,
whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, Third Security shall be deemed not to be an Affiliate of Intrexon or NewCo, and neither Party shall be deemed to be an Affiliate of the
other Party. In addition, any other person, corporation, partnership, or other entity that would be an Affiliate of Intrexon or NewCo solely because it and Intrexon are under common control by Randal J. Kirk or by investment funds managed by Third
Security or an affiliate of Third Security shall also be deemed not to be an Affiliate of Intrexon or NewCo. 








 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.2 “Applicable Laws” has the meaning set forth in Section
8.2(d)(xii). 
 1.3 “Authorizations” has the meaning set forth in Section 8.2(d)(xii).  

1.4 “Biofuels Program” means the channel collaboration between the Parties as established and governed by this
Agreement.  
 1.5 “Biomass” means the biodegradable fraction of Target Products, including residues from the
bioconversion processes in the Biofuels Program.  
 1.6 “Channel-Related Program IP” has the meaning set
forth in Section 6.1(c). 
 1.7 “Claims” has the meaning set forth in Section 9.1.  

1.8 “Collaboration Products” means any product in the Field that is created, produced, developed, or identified in whole or
in part, directly or indirectly, by or on behalf of NewCo during the Term through use or practice of Intrexon Channel Technology, Intrexon IP, or the Intrexon Materials.  

1.9 “Committees” has the meaning set forth in Section 2.2(a). 

1.10 “Commercialize” or “Commercialization” means any activities directed to marketing, promoting,
distributing, importing for sale, offering to sell and/or selling Collaboration Products. 
 1.11 “Commercial
Sale” means for a given product and country the sale for value of that product by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval (if necessary) has been
obtained for such product in such country. 
 1.12 “Complementary In-Licensed Third Party IP” has the meaning set
forth in Section 3.8(a). 
 1.13 “Confidential Information” means each Party’s confidential Information,
disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties, regardless of whether in oral, written, graphic or electronic form. 

1.14 “Control” means, with respect to Information, a Patent or other intellectual property right, that a Party owns or
has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party.


  
 2 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.15 “Diligent Efforts” means, with respect to a Party’s
obligation under this Agreement, the level of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Collaboration Product in a sustained manner, consistent with the efforts and
resources a similarly situated company working in the Field would typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based on market conditions then prevailing. With respect to
a particular task or obligation, Diligent Efforts requires that the applicable Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed to advance progress with respect to such
task or obligation. 
 1.16 “EPA” has the meaning set forth in Section 8.2(d)(xii). 

1.17 “Excess Product Liability Costs” has the meaning set forth in Section 9.3. 

1.18 “Executive Officer” means : (a) the Chief Executive Officer of the applicable Party, or (b) another
senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative of the Party to resolve, as the case may be, (i) a Committee dispute, provided that such appointed officer is not a
member of the applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable Committee, or (ii) a dispute described in Section 11.1. 

1.19 “FDA” has the meaning set forth in Section 8.2(d)(xii). 

1.20 “Field” means (i) the research and development of technology used in the microbial conversion of natural gas
to Target Products, (ii) the building and development of platform(s) for such bioconversion processes, (iii) the proving of such platform(s), (iv) the Commercialization of such platform(s) and (v) the further leveraging of such
platform(s) for the production of Target Products. For clarity, the Field does not include the sale of Biomass or other ancillary derivatives of any process developed through the implementation of bioconversion processes.  

1.21 “Field Infringement” has the meaning set forth in Section 6.3(b).  

1.22 “Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect charges and
overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject to the approval of a project and its associated budget by the JSC and the terms of Section 4.5, Intrexon will bill for its
internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good, product or service. Intrexon
may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide NewCo with reasonable
documentation indicating the basis for any direct and indirect charges, any allocable overhead, and any such adjustment in full-time equivalent rate. 

1.23 “In-Licensed Program IP” has the meaning set forth in Section 3.8(a). 

  
 3 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.24 “Information” means information, results and data of any type
whatsoever, in any tangible or intangible form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including
pharmacological, biological, chemical, biochemical, toxicological and regulatory test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal information or descriptions. 

1.25 “Infringement” has the meaning set forth in Section 6.3(a). 

1.26 “Intrexon Channel Technology” means Intrexon’s current and future technology directed towards the design,
identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation the following of
Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) LEAPTM, (3) DNA and RNA MOD engineering,
(4) protein engineering, (5) transcription control chemistry, (6) genome engineering, and (7) cell system engineering. 

1.27 “Intrexon Indemnitees” has the meaning set forth in Section 9.2. 

1.28 “Intrexon IP” means the Intrexon Patents and Intrexon Know-How. 

1.29 “Intrexon Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by Intrexon
as of the Effective Date or during the Term and (b) is reasonably required or useful for NewCo to conduct the Biofuels Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other than Intrexon Patents) in the
Channel-Related Program IP. 
 1.30 “Intrexon Materials” means the nucleotides and amino acids associated with their
corresponding genetic code and gene constructs, in each case that are Controlled by Intrexon (used alone or in combination and such other proprietary reagents) and biological materials including but not limited to plasmid vectors, bacteria, growth
media, virus stocks, cells and cell lines, antibodies, and ligand-related chemistry, in each case that are reasonably required or provided to NewCo by or on behalf of Intrexon to conduct the Biofuels Program.  

1.31 “Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date or during
the Term; and (b) are reasonably required or useful for NewCo to conduct the Biofuels Program. For the avoidance of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP. 

1.32 “Intrexon Trademarks” means those trademarks related to the Intrexon Channel Technology that are established from
time to time by Intrexon for use across its channel partnerships or collaborations. 
 1.33 “Inventions” has
the meaning set forth in Section 6.1(b). 

  
 4 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.34 “IPC” has the meaning set forth in Section 2.2(b). 

1.35 “JSC” has the meaning set forth in Section 2.2(b).  

1.36 “Losses” has the meaning set forth in Section 9.1. 

1.37 “Lubricant Base Oils” means Group I, Group II and Group III lubricant base oils as designated as of the date
hereof by the American Petroleum Institute. 
 1.38 “NewCo Indemnitees” has the meaning set forth in Section
9.1. 
 1.39 “NewCo Program Patent” has the meaning set forth in Section 6.2(b). 

1.40 “NewCo Termination IP” means all Patents or other intellectual property that NewCo or any of its Affiliates
Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the development, manufacture or Commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field.

 1.41 “Patents” means (a) all patents and patent applications (including provisional applications),
(b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination, confirmations, re-examinations, extensions, supplementary protection certificates and the like of the
foregoing, and (c) any foreign or international equivalents of any of the foregoing. 
 1.42 “Product-Specific
Program Patent” means any issued Intrexon Patent where all the claims are directed to Inventions that relate solely and specifically to Collaboration Products. In the event of a disagreement between the Parties as to whether a particular
Intrexon Patent is or is not a Product-Specific Program Patent, the Parties shall seek to resolve the issue through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted to
arbitration pursuant to Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific
Program Patent or (b) an arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent. 

1.43 “Product Sublicense” has the meaning set forth in Section 3.2(c). 

1.44 “Product Sublicensee” has the meaning set forth in Section 3.2(c). 

1.45 “Proposed Terms” has the meaning set forth in Section 11.2. 

1.46 “Prosecuting Party” has the meaning set forth in Section 6.2(c). 

1.47 “Recovery” has the meaning set forth in Section 6.3(f). 

  
 5 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 1.48 “Retained Product” has the meaning set forth in Section
10.4(a). 
 1.49 “Reverted Product” has the meaning set forth in Section 10.4(c). 

1.50 “SEC” means the United States Securities and Exchange Commission. 

1.51 “Superior Product” means a product produced in the Field that, based on the data then available,
(a) demonstrably appears to offer either superior yield, safety or significantly lower cost of production, as compared with both (i) those products that are marketed (either by NewCo or others) at such time for similar commercial use and
(ii) those products that are being actively developed by NewCo for such purpose; (b) demonstrably appears to represent a substantial improvement over such existing products; and (c) has intellectual property protection and a
regulatory approval pathway that, in each case, would not present a significant barrier to commercial development. 
 1.52
“Supplemental In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a). 
 1.53
“Support Memorandum” has the meaning set forth in Section 11.2. 
 1.54 “Target
Products” means the following classes of liquid fuels and lubricants, as well as components of such fuels and lubricants that represent at least 5% by weight of such fuels and lubricant: motor gasoline; aviation turbine fuel for both
commercial and military specifications; on and off-road diesel fuel; and Lubricant Base Oils.  
 1.55 “Technology
Access Fee” for the purposes of this Agreement has the meaning as set forth in Section 5.1. 
 1.56
“Term” has the meaning set forth in Section 10.1. 
 1.57 “Territory” means the
world. 
 1.58 “Third Party” means any individual or entity other than the Parties or their respective
Affiliates. 
 1.59 “Third Security” means Third Security, LLC, a Virginia limited liability company.

 1.60 “US GAAP” means generally accepted accounting principles in the United States. 

  
 6 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 2 

SCOPE OF CHANNEL COLLABORATION; MANAGEMENT 

2.1 Scope. 
 (a)
Generally. The general purpose of the Biofuels Program described in this Agreement will be to use the Intrexon Channel Technology to research, develop and Commercialize Collaboration Products. As provided below, the JSC shall establish, monitor,
and govern projects for Collaboration Products. Either Party may propose other potential projects in the Field for review and consideration by the JSC. 

2.2 Committees. 

(a) Generally. The Parties desire to establish several committees (collectively, “Committees”) to oversee the Biofuels
Program and to facilitate communications between the Parties with respect thereto. Each of such Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the obligation to exercise
its authority consistent with the respective purpose for such Committee as stated herein and any such decisions shall be made in good faith. 

(b) Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then create the JSC and the IPC. Each
Committee shall have the purpose indicated in the chart. 
  

			
	 Committee
	  	 Purpose

	 Joint Steering Committee (“JSC”)
	  	Establish projects for the Biofuels Program and establish the priorities, as well as establish and approve budgets for such projects. Approve all subcommittee projects and plans. The JSC shall establish budgets not less than on a
quarterly basis.
		
	 Intellectual Property Committee (“IPC”)
	  	Evaluate intellectual property issues in connection with the Biofuels Program; review and approve itemized budgets with respect to the foregoing.


  
 7 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 2.3 General Committee Membership and Procedure. 

(a) Membership. For each Committee, each Party shall designate an equal number of representatives (not to exceed three (3) for
each Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the representatives must all be
employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other Committee up to one (1) representative who is not an employee if: (i) such non-employee representative agrees in
writing to be bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties, and (ii) the other Party consents to the designation of such non-employee representative, which
consent shall not be unreasonably withheld. Each representative as qualified above may serve on more than one (1) Committee as appropriate in view of the individual’s expertise. Each Party may replace its Committee representatives at any
time upon written notice to the other Party. Each Committee shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative to the Committee will act as chairperson shall
alternate between the Parties, with NewCo selecting the chairperson first for the JSC, and Intrexon selecting the chairperson first for the IPC. The chairperson of each Committee shall be responsible for calling meetings, preparing and circulating
an agenda in advance of each meeting of such Committee, and preparing and issuing minutes of each meeting within fifteen (15) days thereafter. 

(b) Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall such meetings be held less
frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the
so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication
(telephone, video, or web conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location for such in-person meetings, with NewCo selecting the first meeting location for each
Committee. A reasonable number of additional representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all of its own expenses of participating in any Committee excepting that an
Intrexon employee or agent serving on a Committee shall not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course of providing support services as set forth in
Section 4.5 below. 
 (c) Meeting Agendas. Each Party will disclose to the other proposed agenda items along with
appropriate information at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its agenda items to the other Party within a lesser period of time in advance of the meeting, or
may propose that there not be a specific agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence of a specific agenda for such Committee meeting. 

  
 8 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (d) Limitations of Committee Powers. Each Committee shall have only such powers as are
specifically delegated to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute for the rights of the Parties. Without limiting the generality of the foregoing, no Committee
shall have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below. Additionally, no member of any Committee shall be able to vote in such Committee and
thereby bind its respective Party on any material matter accept as otherwise properly authorized, approved, or delegated by such Party in accord with Section 2.5. 

2.4 Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter within thirty (30) days
of its initial consideration of such matter, then either Party may provide written notice of such dispute to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or by means of
telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is
not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such Executive Officers, then the Executive Officer of the Party specified in the applicable subsection below shall have the authority to finally
resolve such dispute acting in good faith.  
 (a) Casting Vote at JSC. If a dispute at the JSC is not resolved pursuant to
Section 2.4 above, then the Executive Officer of NewCo shall have the authority to finally resolve such dispute. 
 (b)
Casting Vote at IPC. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the
Parties with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and any such disputes shall be resolved pursuant to Article 11). 

(c) Other Committees. If any additional Committee or subcommittee other than those set forth in Section 2.2(b) is formed, then the
Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute that is not resolved pursuant to Section 2.4 above. 

(d) Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance with this
Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement; (ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights
or other rights specifically allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach of this Agreement; (v) resolves a matter if the provisions of this Agreement
specify that mutual agreement is required for such matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law. 

  
 9 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 2.5 Authorization of Committee Representatives. Each representative serving on a
Committee shall be responsible for ensuring that he or she acts only as duly authorized by its respective Party and obtains any advance approvals, delegations, or other authorizations from his or her respective Party in advance of making any
Committee votes. Any Committee representative shall only be able to bind its respective appointing Party via any Committee vote or other material Committee activity to the extent such vote or other activity has been previously approved by the Party,
is within the authority duly delegated to the representative by the respective Party, or is otherwise authorized by its respective Party as may be required by that Party’s corporate charter or bylaws, or by its board of directors. Any action or
vote taken without valid authority shall be considered null and void and shall be without effect unless subsequently approved by a vote in accord with this Section 2.5.  

ARTICLE 3 

LICENSE GRANTS 

3.1 Licenses to NewCo.  

(a) Subject to the terms and conditions of this Agreement, Intrexon hereby grants to NewCo a license under the Intrexon IP to research,
develop, use, make, have made, import, export, sell, and offer for sale Collaboration Products in the Field in the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any development, selling, offering for sale or other
Commercialization of Collaboration Products in the Field, and shall be otherwise non-exclusive.  
 (b) Subject to the terms
and conditions of this Agreement, prior to marketing any Collaboration Product, NewCo and Intrexon will separately negotiate a non-exclusive license to use and display Intrexon Trademarks, solely in connection with the Commercialization of
Collaboration Productions in the promotional materials, packaging and labeling. NewCo covenants that it shall not use any trademark confusingly similar to any Intrexon Trademarks in connection with any products (including any Collaboration Product).
 
 3.2 Sublicensing. Except as provided in this Section 3.2, NewCo shall not sublicense the rights granted under
Section 3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to research, develop, use, or Commercialize Collaboration Products, in each case except with Intrexon’s
written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the foregoing, NewCo shall have a limited right to sublicense under the circumstances described in Section 3.2(a). 

(a) NewCo may, with Intrexon’s written consent, which consent shall not be unreasonably withheld, sublicense the rights granted
under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate. In the event that Intrexon consents to any such grant or transfer to an Affiliate, NewCo shall remain responsible for, and be guarantor of, the performance
by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection with such performance (as though such Affiliate were NewCo), including any payment obligations owed to Intrexon hereunder. 


  
 10 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 3.3 Limitation on Sublicensees. None of the enforcement rights under the Intrexon
Patents that are granted to NewCo pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior written consent, which may be withheld in Intrexon’s sole discretion. 

3.4 No Non-Permitted Use. NewCo hereby covenants that it shall not, nor shall it permit any Affiliate or, if applicable, (sub)licensee,
to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or Intrexon Materials for any purposes other than those expressly permitted by this Agreement. 

3.5 Exclusivity. Neither Intrexon nor its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials available to any
Third Party for the purpose of developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate shall pursue (either by itself or with a Third Party or Affiliate) the research,
development or Commercialization of any product for purpose of commercial use or sale in the Field, outside of the Biofuels Program. Further, neither NewCo nor its Affiliates shall pursue (either by itself or with a Third Party or Affiliate) outside
of the Biofuels Program the research, development or Commercialization of any product for purpose of commercial use or sale in the Field where such products would compete with Collaboration Products.  

3.6 No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement shall prevent
Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose, and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, NewCo acknowledges that
Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology (including any genetic materials used in an Collaboration Product), and Intrexon IP available to Third Party channel partners or
collaborators for use in fields outside the Field.  
 3.7 Rights to Regulatory Data. NewCo shall own and control all
regulatory data and regulatory filings relating to Commercialization of Collaboration Products (except to the extent such become Reverted Products). NewCo shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon at
Intrexon’s written request full copies of all regulatory data and reports, regulatory filings, and communications from regulatory authorities that relate specifically and solely to Collaboration Products. To the extent that there exist any
regulatory data and reports, regulatory filings, and communications from regulatory authorities owned by NewCo (or a Product Sublicensee) that relate both to Collaboration Products and other products produced by NewCo (or a Product Sublicensee)
outside the Field, upon Intrexon’s written request NewCo shall provide (or shall cause an applicable Product Sublicensee to provide) to Intrexon copies of the portions of such data, reports, filings, and communications that 


  
 11 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
relate to Collaboration Products. Subject to its ongoing obligations of exclusivity under Section 3.5, Intrexon shall be permitted, directly or in conjunction with or through partners or
other channel collaborators, to reference this data, reports, filings, and communications relating to Collaboration Products in regulatory filings made to obtain regulatory approval for products for use in fields outside the Field. Intrexon shall
have the right to use any such information in developing and Commercializing products outside the Field and to license any Third Parties to do so. Notwithstanding the provisions of this Section 3.7, Intrexon shall not, outside of the Biofuels
Program, utilize knowingly any NewCo data or reports in support of obtaining regulatory approval for a product for use in the Field. 

3.8 Third Party Licenses. 

(a) [*****] shall be responsible for obtaining, at its sole expense, (i) intellectual property licenses directed to any specific
target genes, genetic transformation methodologies, manufacturing cell lines, bioconversion processes, or intermediates thereof, or processes or methods for commercially manufacturing Target Products that [*****] determines, in its own discretion,
are necessary for activities under the JSC established plans and (ii) any intellectual property licenses from Third Parties that [*****] determines, in its sole discretion, are required in order to lawfully make, use, sell, offer for sale, or
import Target Products, including licenses under Patents that may pertain to Target Products (collectively, “Complementary In-Licensed Third Party IP”). Accordingly, [*****] shall have no obligation to obtain Complementary
In-Licensed Third Party IP or otherwise obtain license rights under any Complementary In-Licensed Third Party IP Controlled by any Third Party. Subject to the foregoing, [*****] may obtain, at its sole option and sole expense, any intellectual
property licenses from Third Parties that [*****] determines may be desirable for the general practice of Intrexon’s platform areas and capabilities of the Intrexon Channel Technology (“Supplemental In-Licensed Third Party
IP”). For clarity, Supplemental In-Licensed Third Party IP is not (and does not include) Complementary In-Licensed Third Party IP. Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively
referred to as “In-Licensed Program IP”.  
 (b) In the event that either Party desires to license from a
Third Party any Information or intellectual property from a Third Party that may be materially relevant to the Target Products, such Party shall so notify the other Party, and the IPC shall discuss such and its potential applicability to the Target
Products and to the Field. 
 (c) [*****] shall provide the proposed terms of any license under Complementary In-Licensed
Third Party IP and the final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion prior to signing, and shall consider [*****] comments thereto in good faith. To the extent
that [*****] obtains a license under intellectual property of a Third Party that the IPC concludes is not Complementary In-Licensed Third Party IP but which the IPC reasonably concludes has a reasonable likelihood of being material to the Biofuels
Program, [*****] shall provide the final version of the definitive license agreement for such to the IPC for review and  

  
 12 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
discussion prior to signing, and shall consider Intrexon’s comments thereto in good faith. If [*****] acquires rights under any In-Licensed Program IP outside the Field, it will do so on
a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be exclusive. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.8
shall keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity, (i) any costs incurred by [*****] in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall
be borne solely by [*****], and (ii) any costs incurred by [*****] in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP shall be borne solely by [*****]. 

(d) For any Third Party license under which NewCo or its Affiliates obtain a license under Patents claiming inventions or know-how
specific to or used or incorporated into the development, manufacture, and/or Commercialization of Collaboration Products, NewCo shall use commercially reasonable efforts to ensure that NewCo will have the ability, pursuant to Section 10.4(h),
to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)). 

(e) The licenses granted to NewCo under Section 3.1 may include sublicenses under Intrexon IP that has been licensed to Intrexon
by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable upstream license agreement, subject to the cost allocation set forth in Section 3.8(c), provided that Intrexon
shall either provide unredacted copies of such upstream license agreements to NewCo or shall disclose in writing to NewCo all of such terms and conditions that are applicable to NewCo. NewCo shall not be responsible for complying with any provisions
of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to NewCo as provided in the preceding sentence. 

(f) If either Party receives notice from a Third Party concerning activities of a Party taken in conjunction with performance of
obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents or other intellectual property rights owned or controlled by that Third Party, the receiving Party shall inform the other party
thereof within five (5) business days. 
 3.9 Licenses to Intrexon. Subject to the terms and conditions of this Agreement, NewCo
hereby grants to Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property Controlled by NewCo or its Affiliates, solely to the extent necessary for Intrexon to conduct those
responsibilities assigned to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any Intrexon subcontractors as permitted in accord with Section 4.5 in conjunction with support services
(subject to JSC research plan approval). 

  
 13 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 3.10 Restrictions Relating to Intrexon Materials. NewCo and its permitted sublicensees
shall use the Intrexon Materials solely for purposes of the Biofuels Program and not for any other purpose without the prior written consent of Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology,
NewCo shall not, and shall ensure that NewCo personnel and permitted sublicensees do not, except as otherwise permitted in this Agreement (a) distribute, sell, lend or otherwise transfer such Intrexon Materials to any Third Party;
(b) co-mingle such Intrexon Materials with any other proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or in any way attempt to reverse engineer or sequence such
Intrexon Materials.  
 ARTICLE 4 

OTHER RIGHTS AND OBLIGATIONS 

4.1 Development and Commercialization. Subject to Section 4.5, NewCo shall be solely responsible for the development and
Commercialization of Collaboration Products. NewCo shall be responsible for all costs incurred in connection with the Biofuels Program except that Intrexon shall be responsible for the following: (a) costs of basic research with respect to the
Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.5 or research requested by the JSC for the development of a
Collaboration Product (which research costs shall be reimbursed by NewCo); (b) [*****]; and (c) costs of filing, prosecution and maintenance of Intrexon Patents.  

4.2 Information and Reporting. NewCo will keep Intrexon informed about NewCo’s efforts to develop and Commercialize Collaboration
Products, including reasonable and accurate summaries of NewCo’s (and its Affiliates’ and, if applicable, (sub)licensees’) development plans (as updated), including regulatory plans, marketing plans (as updated), progress towards
meeting the goals and milestones in such plans and explanations of any material deviations, significant developments in the development and/or Commercialization of the Collaboration Products, including initiation or completion of a regulatory trial,
submission of a United States or international regulatory filing, receipt of a response to such United States or international regulatory filing, product safety event, receipt of regulatory approval, or commercial launch, and manufacturing costs and
pricing information. As set forth in Section 3.7 above, NewCo shall also provide to Intrexon copies of all final regulatory documents and reports. Intrexon will keep NewCo informed about Intrexon’s efforts to undertake discovery-stage
research for the Biofuels Program with respect to the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein or directed by the JSC in accord with Section 4.1 above, such disclosures by NewCo and Intrexon will be
coordinated by the JSC and made in connection with JSC meetings at least once every six (6) months while Collaboration Products are being developed or Commercialized anywhere in the world, and shall be reflected in the minutes of such meetings.
 
 4.3 Regulatory Matters. At all times after the Effective Date, NewCo shall own and maintain, at its own cost, all
regulatory filings and regulatory approvals for Collaboration Products that NewCo is developing or Commercializing pursuant to this Agreement. As such, NewCo shall be responsible for reporting all adverse events related to such Collaboration
Products to the appropriate regulatory authorities in the relevant countries, in accordance with  

  
 14 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
the applicable laws and regulations of such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon Materials outside of the
Field, Intrexon may request that NewCo and Intrexon establish and execute a separate safety data exchange agreement, which agreement will address and govern the timely exchange of safety information generated by NewCo, Intrexon, and relevant third
parties with respect to specific Intrexon Materials. 
 4.4 Diligence.  

(a) NewCo shall use, and shall require its sublicensees to use, Diligent Efforts to develop and Commercialize Collaboration
Products. 
 (b) Without limiting the generality of the foregoing, Intrexon may, from time to time, notify NewCo that it
believes it has identified a Superior Product, and in such case Intrexon shall provide to NewCo its then-available information about such product and reasonable written support for its conclusion that the product constitutes a Superior Product.
NewCo shall have the following obligations with respect to such proposed Superior Product: (i) within sixty (60) days after such notification, NewCo shall prepare and deliver to the JSC for review and approval a development plan detailing
how NewCo will pursue the Superior Product (including a proposed budget); (ii) NewCo shall revise the development plan as directed by the JSC; and (iii) following approval of the development plan by the JSC, NewCo shall use Diligent
Efforts to pursue the development of the Superior Product under the Biofuels Program in accordance with such development plan. If NewCo fails to comply with the foregoing obligations, or if NewCo unreasonably exercises its casting vote at the JSC to
either (x) prevent the approval of a development plan for a Superior Product; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC; or (z) approve a development plan that is
insufficient in view of the nature and magnitude of the opportunity presented by the Superior Product, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth therein). For clarity, any
dispute arising under this 4.4, including any dispute as to whether a proposed project constitutes a Superior Product (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article 11.  

(c) The activities of NewCo’s Affiliates and any permitted sublicensees shall be attributed to NewCo for the purposes of
evaluating NewCo’s fulfillment of the obligations set forth in this Section 4.4. 
 4.5 Support Services. The JSC will
meet promptly following the Effective Date and establish a plan under which Intrexon will provide support services to NewCo for the research and development of Collaboration Products under the Biofuels Program, which initial plan may be amended from
time to time by the JSC. NewCo will compensate Intrexon for such support services with cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. Additionally, from time to time, on an ongoing basis, NewCo shall
request, or Intrexon may propose, that Intrexon perform certain additional support services with respect to  

  
 15 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
researching and developing new Collaboration Products or improving the manufacturing or processing methods for any existing Collaboration Products. To the extent that the Parties mutually
agree that Intrexon should perform such additional services, the Parties shall negotiate in good faith the terms under which services would be performed, it being understood that Intrexon would be compensated for such services by cash payments equal
to Intrexon’s Fully Loaded Cost in connection with such services. 
 4.6 Compliance with Law. Each Party shall comply,
and shall ensure that its Affiliates, (sub)licensees and Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Biofuels Program, including without limitation those relating to the transport, storage,
and handling of Intrexon Materials and Collaboration Products. 
 4.7 Patent Marking. Consistent with the U.S. patent laws,
NewCo shall ensure that Collaboration Products appropriately identify Intrexon Patents. NewCo shall provide Intrexon with copies of any materials containing the patent markings prior to using or disseminating such materials, in order to obtain
Intrexon’s approval thereof. NewCo’s use of the patent markings shall be subject to prior review and approval of the IPC. From time to time during the Term, Intrexon shall have the right to obtain from NewCo samples of Collaboration
Product sold by NewCo or its Affiliates or sublicensees, or other items which reflect public uses of patent markings, for the purpose of inspecting the quality of such Collaboration Products or the accuracy of the patent markings. In the event that
Intrexon inspects under this Section 4.7, Intrexon shall notify the result of such inspection to NewCo in writing thereafter. 

ARTICLE 5 

COMPENSATION 

5.1 Technology Access Fee. In partial consideration for NewCo’s appointment as an exclusive channel collaborator in the Field and
the other rights granted to NewCo hereunder and as an access fee for commercial license rights to the Intrexon IP granted under Section 3.1, NewCo shall pay to Intrexon a one time cash payment of twenty-five million United States dollars
($25,000,000) (the “Technology Access Fee”). The Technology Access Fee shall be paid within three (3) business days by NewCo, and the receipt of such payment by Intrexon is a condition subsequent to the effectiveness of this
Agreement.  
 5.2 Method of Payment. Payments due to Intrexon under this Agreement shall be paid in United States dollars by
wire transfer to a bank in the United States designated in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars. 

  
 16 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 5.3 Audits. 

(a) Upon the written request of Intrexon, NewCo shall permit an independent certified public accounting firm of internationally
recognized standing selected by Intrexon, and reasonably acceptable to NewCo, to have access to and to review, during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of NewCo and its
Affiliates to verify the accuracy and timeliness of the reports and payments made by NewCo under this Agreement. Such review may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of
such request. The accounting firm shall disclose to both Parties whether the royalty reports and/or know-how reports conform to the provisions of this Agreement and/or US GAAP, as applicable, and the specific details concerning any
discrepancies. Such audit may not be conducted more than once in any calendar year. 
 (b) If such accounting firm concludes
that additional amounts were owed during such period, NewCo shall pay additional amounts, with interest from the date originally due as set forth in Section 5.5, within thirty (30) days of receipt of the accounting firm’s written
report. If the amount of the underpayment is greater than five percent (5%) of the total amount actually owed for the period audited, then NewCo shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon shall
pay all costs of the audit. In the event of overpayment, any amount of such overpayment shall be fully creditable against amounts payable for the immediately succeeding calendar quarter(s). 

(c) Intrexon shall (i) treat all information that it receives under this Section 5.3 in accordance with the confidentiality
provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with NewCo obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement,
in each case except to the extent necessary for Intrexon to enforce its rights under this Agreement. 
 5.4 Taxes. The Parties
will cooperate in good faith to obtain the benefit of any relevant tax treaties to minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. NewCo shall deduct or withhold from any payments any taxes that
it is required by applicable law to deduct or withhold. Notwithstanding the foregoing, if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding tax, it may deliver to NewCo
or the appropriate governmental authority (with the assistance of NewCo to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve
NewCo of its obligation to withhold tax, and NewCo shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be, provided that NewCo has received evidence of Intrexon’s delivery of all applicable forms
(and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the payment is due. If, in accordance with the foregoing, NewCo withholds any amount, it shall make timely payment to
the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45) days following that latter payment. 

5.5 Late Payments. Any amount owed by NewCo to Intrexon under this Agreement that is not paid within the applicable time period set
forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b) the highest rate permitted under applicable law. 

  
 17 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1 Ownership. 

(a) Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with Intrexon. 

(b) NewCo and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries, inventions, processes, techniques,
and other technology, whether or not patentable, in the course of performing the Biofuels Program (collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed written description of any such
Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws. 
 (c)
Intrexon shall solely own all right, title and interest in all Inventions made with, using, or otherwise incorporating Intrexon Channel Technology, together with all Patent rights and other intellectual property rights therein (the
“Channel-Related Program IP”). NewCo hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to Intrexon. NewCo agrees to execute such documents and perform such other acts as Intrexon may
reasonably request to obtain, perfect and enforce its rights to the Channel-Related Program IP and the assignment thereof. 
 (d)
Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or other technology, whether or not patentable, that is conceived, reduced to practice or developed by NewCo solely or jointly through the
use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon and
shall be included in the Channel-Related Program IP. 
 (e) All Information regarding Channel-Related Program IP shall be
Confidential Information of Intrexon. NewCo shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Biofuels Program, pursuant to which such person shall grant all rights in the Inventions to
NewCo (so that NewCo may convey certain of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Biofuels Program. 

6.2 Patent Prosecution. 

(a) Intrexon shall have the sole right, but not the obligation, to (i) conduct and control the filing, prosecution and maintenance
of the Intrexon Patents, and (ii) conduct and control the filing, prosecution, and maintenance of any applications for patent term extension 

  
 18 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
and/or supplementary protection certificates that may be available as a result of the regulatory approval of any Collaboration Product. Notwithstanding the foregoing, NewCo may request that
Intrexon pursue a patent for a Collaboration Product, and, if Intrexon declines to do so, then the issue shall be referred to and resolved by the IPC. At the reasonable request of Intrexon, NewCo shall cooperate with Intrexon in connection with such
filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall NewCo (i) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United States or
elsewhere, that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon, (ii) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or
any Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or
(iii) without prior approval of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension or supplementary protection certificate, either in the United States or elsewhere,
that relies upon the regulatory approval of an Collaboration Product. 
 (b) NewCo shall have the sole right, but not the
obligation, to conduct and control the filing, prosecution and maintenance of any Patents claiming Inventions that are owned by NewCo or its Affiliates and not assigned to Intrexon under Section 6.1(c) (“NewCo Program
Patents”). At the reasonable request of NewCo, Intrexon shall cooperate with NewCo in connection with such filing, prosecution, and maintenance, at NewCo’s expense. 

(c) As used in this Section, “Prosecuting Party” means Intrexon in the case of Intrexon Patents and NewCo in the case
of NewCo Program Patents. The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution
of the Intrexon Patents and NewCo Program Patents, as applicable. The Prosecuting Party shall: 
 (i) regularly provide the other
Party in advance with reasonable information relating to the Prosecuting Party’s prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant
patent authorities and copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible to the public,
the Prosecuting Party may, in lieu of directly providing copies of such information to such other Party, provide such other Party with sufficient information that will permit such other Party to access such information itself directly); 

(ii) consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; provided,
however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment, the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may
have comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon; 

  
 19 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (iii) consult with the non-Prosecuting Party before taking any action that would reasonably
be expected to have a material adverse impact on the scope of claims within the Intrexon Patents and NewCo Program Patents, as applicable. 

6.3 Infringement of Patents by Third Parties. 

(a) Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take appropriate
action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action.  
 (b) Notwithstanding the foregoing, NewCo shall have the first right, but not the obligation, to take
appropriate action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly infringing activities in the Field (“Field Infringement”), either by settlement or
lawsuit or other appropriate action. If NewCo exercises the foregoing right, Intrexon agrees to be named in any such action if required. If NewCo fails to take the appropriate steps to enforce Product-Specific Program Patents against any Field
Infringement within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of such Field Infringement, then Intrexon shall have the right (but not the obligation), at its own
expense, to enforce Product-Specific Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action. 

(c) With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific Program Patents
pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action:
(i) enforce one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [*****]. To the extent NewCo shall be entitled to a share of the Recovery a set forth in
Section 6.3(f), Intrexon and NewCo shall bear the costs and expenses of such enforcement equally. The determination of which Intrexon Patent(s) to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall
consult in good faith with NewCo on such determination. For the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents against, or otherwise abate, any Infringement that is not a Field Infringement.

 (d) In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with the
enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses
will be shared equally in accordance with terms thereof). 

  
 20 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (e) NewCo shall not settle or otherwise compromise any action under this
Section 6.3 in a way that diminishes the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written consent, which consent shall not be unreasonably withheld. Intrexon shall
not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes the rights or interests of NewCo in the Field or adversely affects any Intrexon Patent with respect to the Field without NewCo’s prior written
consent, which consent shall not be unreasonably withheld. 
 (f) Except as otherwise agreed to by the Parties in writing, any
settlements, damages or other monetary awards recovered pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of the Party controlling such action, and second, to the costs
and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action initiated by Intrexon pursuant to
Section 6.3(a) that does not involve Field Infringement, or in any action initiated by Intrexon pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by NewCo pursuant to
Section 6.3(b), NewCo shall retain one hundred percent (100%) of any Recovery. In any action initiated by Intrexon or NewCo pursuant to Section 6.3(c), the Parties shall share the Recovery equally. 

(g) NewCo shall promptly notify Intrexon of any suspected, alleged, threatened, or actual Infringement of which it becomes aware, and
Intrexon shall promptly notify NewCo of any suspected, alleged, threatened, or actual Field Infringement of which it becomes aware. 

ARTICLE 7 

CONFIDENTIALITY 

7.1 Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each
Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the other Party pursuant to this
Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential Information: 

(a) was already known to the receiving Party and can be demonstrated by written records, other than under an obligation of
confidentiality, at the time of disclosure by the other Party; 

  
 21 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (b) was generally available to the public or otherwise part of the public domain at
the time of its disclosure to the receiving Party; 
 (c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 

(d) was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by a Third Party who had
no obligation to the disclosing Party not to disclose such information to others; or 
 (e) was independently discovered or
developed by the receiving Party without the use of Confidential Information belonging to the disclosing Party, as documented by the receiving Party’s written records. 

The foregoing non-use and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a
trade secret under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases. 

7.2 Authorized Disclosure. Notwithstanding the limitations in this Article 7, either Party may disclose the Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances: 
 (a) complying with
applicable laws or regulations or valid court orders, provided that the Party making such disclosure provides the other Party with reasonable prior written notice of such request or demand for disclosure and makes a reasonable effort to
obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation required, or
for which the order was issued; 
 (b) to regulatory authorities in order to seek or obtain approval to conduct regulatory trials, or
to gain regulatory approval, of Collaboration Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators, provided that the Party making such disclosure (i) provides the other Party with
reasonable opportunity to review any such disclosure in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information and (ii) does not unreasonably reject any such suggestions;

 (c) disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the
confidentiality of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition, or merger (as the case may be); 

  
 22 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (d) disclosure on a need-to-know basis to Affiliates, licensees, sublicensees,
employees, consultants or agents (such as CROs) who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7; and 

(e) disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators who agree to be
bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article 7. 
 7.3
Publicity; Publications. Following the Effective Date, the Parties will consult to consider, and, if mutually desired, draft and release, a public announcement of the execution of this Agreement substantially in the form of a press release,
which form shall be mutually agreed to by the Parties. Each Party will provide the other Party with the opportunity to review and comment, prior to submission or presentation, on external reports, publications and presentations (e.g., press
releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer to the Biofuels Program, Collaboration Products or programs that are approved by the JSC. For such reports, publications, and presentations,
the disclosing Party will provide the other Party at least fifteen (15) calendar days for review of the proposed submission or presentation. In the case of a Form 8-K filing, such shall be provided by Intrexon to NewCo as soon as practicable
prior to filing. For reports and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the report or manuscript. The presenting Party will act in good faith to incorporate the comments of the
other Party and shall, in any event, redact any Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or presentations if necessary to provide the other Party with sufficient time to prepare and
file any related Patent applications before the submission or presentation occurs, as appropriate. 
 7.4 Terms of the
Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information of other Party, subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that the other Party
may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment of
certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement
marked to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements governing
redaction of information from material agreements that must be publicly filed. The other Party shall promptly provide any such comments. 

  
 23 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 7.5 Proprietary Information and Operational Audits. 

(a) For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence obligations of Article
4, and the confidentiality obligations under Article 7, NewCo acknowledges that Intrexon’s authorized representative(s), during regular business hours may (i) examine and inspect NewCo’s facilities and (ii) inspect all data and
work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection hereunder shall require five (5) business days written notice from Intrexon to NewCo. NewCo will make itself and the
pertinent employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review. 
 (b)
For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the confidentiality obligations under Article 7, Intrexon acknowledges that NewCo authorized representative(s), during regular business hours may
(i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any examination or inspection hereunder shall require five (5) business days written notice from NewCo to
Intrexon. Intrexon will make itself and the pertinent employees and/or agents available, on a reasonable basis, to NewCo for the aforementioned compliance review. 

(c) In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to NewCo hereunder,
Intrexon from time-to-time, but no more than quarterly, may request that NewCo confirm the status of the Intrexon Materials at NewCo (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well as any
amounts returned to Intrexon or destroyed). Within ten (10) business days of NewCo’s receipt of any such written request, NewCo shall provide the written report to Intrexon. 

7.6 Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other licensees and channel partners or
collaborators to enable NewCo to disclose confidential information of such licensees and channel partners or collaborators to regulatory authorities in order to seek or obtain approval to conduct regulatory trials, or to gain regulatory approval of,
Collaboration Products, in a manner consistent with the provisions of Section 7.2(b). 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Representations and Warranties of NewCo. NewCo hereby represents and warrants to Intrexon that, as of the Effective Date:

 (a) Corporate Power. NewCo is duly organized and validly existing under the laws of Delaware and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. NewCo is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on NewCo’s behalf has been duly authorized to do so by all requisite limited liability company action.


  
 24 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (c) Binding Agreement. This Agreement is a legal and valid obligation binding upon
NewCo and enforceable in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to
general equity principles and to limitations on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by NewCo does not conflict with any agreement, instrument or understanding,
oral or written, to which it is a party or by which it may be bound. NewCo is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

8.2 Representations and Warranties of Intrexon. Intrexon hereby represents and warrants to NewCo that, as of the Effective Date:

 (a) Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia and has full corporate power
and authority to enter into this Agreement and to carry out the provisions hereof. 
 (b) Due Authorization. Intrexon is duly
authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person executing this Agreement on Intrexon’s behalf has been duly authorized to do so by all requisite corporate action. 

(c) Binding Agreement. This Agreement is a legal and valid obligation binding upon Intrexon and enforceable in accordance with its
terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and to limitations on
availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement by Intrexon does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by
which it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions or threatens the validity of this Agreement. 

(d) Additional Intellectual Property Representations. 

(i) Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to NewCo with respect to
the Intrexon Patents under this Agreement; 
 (ii) The Intrexon Patents and Intrexon Know-How existing as of the Effective Date constitute
all of the Patents and Know-How Controlled by Intrexon as of such date that are necessary for the development, manufacture and Commercialization of Collaboration Products; 

  
 25 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (iii) Intrexon has not granted, and during the Term Intrexon will not grant, any right or
license, to any Third Party under the Intrexon IP that conflicts with the rights or licenses granted or to be granted to NewCo hereunder; 

(iv) There is no pending litigation, and Intrexon has not received any written notice of any claims or litigation, seeking to invalidate or
otherwise challenge the Intrexon Patents or Intrexon’s rights therein; 
 (v) None of the Intrexon Patents is subject to any pending
re-examination, opposition, interference or litigation proceedings; 
 (vi) All of the Intrexon Patents have been filed and prosecuted in
accordance with all applicable laws and have been maintained, with all applicable fees with respect thereto (to the extent such fees have come due) having been paid; 

(vii) Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved in research and
development work, including development of Intrexon IP, providing Intrexon, to the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived, developed, reduced to practice by such
person, solely or jointly with other of such persons, during the period of employment or contract by Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights granted to NewCo
herein), and Intrexon is not aware that any of its employees or consultants is in material violation thereof; 
 (viii) To Intrexon’s
knowledge, there is no infringement, misappropriation or violation by Third Parties of any Intrexon Channel Technology or Intrexon IP in the Field; 

(ix) There is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against Intrexon that
Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written notice
of such claim; 
 (x) To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving a violation
of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer
(A) where the basis of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee while employed with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel
Technology in the Field; 

  
 26 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (xi) None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to
Intrexon’s knowledge, the Intrexon Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable government agency, in whole or in part, and there is no pending
or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intrexon Patents; and 

(xii) Except as otherwise disclosed in writing to NewCo, Intrexon: (A) is in material compliance with all statutes, rules or regulations
applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development,
manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the United States
Environmental Protection Agency (the “EPA”), the United States Food and Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting
material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which
would, individually or in the aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary for the operation of its business as described in the Field and such Authorizations are valid and in full force
and effect and Intrexon is not in material violation of any term of any such Authorizations; and (D) since January 1, 2012, (1) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from the EPA, the FDA, or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or
Authorizations and has no knowledge that the EPA, the FDA, or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit investigation or
proceeding; (2) has not received notice that the EPA, the FDA or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material
Authorizations and has no knowledge that the EPA, the FDA, or any other federal, state, local or foreign governmental or regulatory authority is considering such action; (3) has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused
to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post sale warning, letters to customers, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged
product defect or violation and, to Intrexon’s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. 

  
 27 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 except, in each of (ix) through (xii), for any instances which would not, individually or in the
aggregate, result in a material adverse effect on the rights granted to NewCo hereunder or Intrexon’s ability to perform its obligations hereunder. 

8.3 Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8, EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER
WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

ARTICLE 9 

INDEMNIFICATION 

9.1 Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend NewCo and its Affiliates and their respective
directors, officers, employees, and agents (collectively, the “NewCo Indemnitees”) from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’ fees)
(collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought by a Third Party (collectively, “Claims”) to the extent arising from (a) the gross negligence or willful
misconduct of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon Materials by or on behalf of Intrexon or its Affiliates, licensees (other than NewCo) or
sublicensees; or (c) breach by Intrexon of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation to indemnify the NewCo Indemnitees to the extent that a Claim arises
from (i) the gross negligence or willful misconduct of NewCo or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by NewCo of a representation, warranty, or covenant of this
Agreement. 
 9.2 Indemnification by NewCo. NewCo agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates and Third
Security and their respective directors, officers, employees, and agents (and any Third Parties which have licensed to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the relevant
upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct of NewCo
or any of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon Materials by or on behalf of NewCo or its Affiliates, licensees, or sublicensees; (c) breach by NewCo of any
material representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling, storage, transport, distribution, sale or other disposition of any Collaboration Product by or on
behalf of NewCo or its Affiliates, licensees, or sublicensees. Notwithstanding the foregoing, NewCo shall not have any obligation to indemnify the Intrexon Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful
misconduct of Intrexon or any of its Affiliates, or their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement. 

  
 28 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 9.3 Product Liability Claims. Notwithstanding the provisions of Section 9.2, any
Losses arising out of any Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising out of or resulting from the development, manufacture or Commercialization of any
Collaboration Products for use or sale in the Field, to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess Product Liability Costs”), shall be
paid by [*****], except to the extent such Losses arise out of any Third-Party Claim based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ sublicensees, or any of the respective officers, directors,
employees and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement. 

9.4 Control of Defense. As a condition precedent to any indemnification obligations hereunder, any entity entitled to indemnification
under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification obligations of this
Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory to the indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The indemnified Party
may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim. The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without
the indemnifying Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim if such settlement (a) does not fully and unconditionally release the indemnified Party from all
liability relating thereto or (b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified Party otherwise agrees in writing. 

9.5 Insurance. Immediately prior to, and during marketing of Collaboration Products, NewCo shall maintain in effect and good standing a
product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately prior to, and during the conduct of any regulatory trials, NewCo shall maintain in effect and good standing a
regulatory trials liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s reasonable request, NewCo shall provide Intrexon with all details regarding such policies,
including without limitation copies of the applicable liability insurance contracts. NewCo shall use reasonable efforts to include Intrexon as an additional insured on any such policies and provide Intrexon with at least 30 days’ notice of
cancellation of any such policies. 

  
 29 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 ARTICLE 10 

TERM; TERMINATION 

10.1 Term. The term of this Agreement shall commence upon the Effective Date and shall continue until the twentieth anniversary of the
Effective Date unless terminated prior to such date pursuant to Section 10.2 or 10.3 (the “Term”). Such Term may be extended by the mutual written agreement of the Parties. 

10.2 Termination for Material Breach; Termination under Section 4.4(b) 

(a) Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other Party commits any
material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written notice from the nonbreaching Party specifying such breach. 

(b) Intrexon shall have the right to terminate this Agreement, at its sole discretion, the Technology Access Fee has not been paid in
accordance with Section 5.1. 
 (c) Intrexon shall have the right to terminate this Agreement under the circumstances set forth in
Section 4.4(b) upon written notice to NewCo, such termination to become effective sixty (60) days following such written notice unless NewCo remedies the circumstances giving rise to such termination within such sixty (60) day period.

 (d) Intrexon shall have the right to terminate this Agreement should NewCo execute any purported assignment of this Agreement
contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice to NewCo and becoming effective immediately upon such written notice. 

10.3 Termination by NewCo. NewCo shall have the right to voluntarily terminate this Agreement in its entirety upon ninety
(90) days written notice to Intrexon at any time. 
 10.4 Effect of Termination. In the event of termination of this
Agreement pursuant to Section 10.2 or Section 10.3, the following shall apply: 
 (a) Retained Products. NewCo shall
be permitted to continue the development and Commercialization in the Field of any product resulting from the Biofuels Program that, at the time of termination, is being sold commercially by NewCo (or, as may be permitted under this Agreement, its
Affiliates and, if applicable, (sub)licensees) (a “Retained Product”). Such right to continue development and Commercialization shall be subject to NewCo’s full compliance with the payment provisions in Article 5, a continuing
obligation for NewCo to use Diligent Efforts in accord with Section 4.4(a) to develop and Commercialize any Retained Products, and all other provisions of this Agreement that survive termination. 

  
 30 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (b) Termination of Licenses. Except as necessary for NewCo to continue to obtain
regulatory approval for, develop, use, manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all rights and licenses granted by Intrexon to NewCo under this Agreement shall terminate and shall revert
to Intrexon without further action by either Intrexon or NewCo. NewCo’s license with respect to Retained Products shall be exclusive or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1. 

(c) Reverted Products. All Collaboration Products other than the Retained Products shall be referred to herein as the “Reverted
Products.” NewCo shall immediately cease, and shall cause its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and NewCo shall not use or practice, nor shall
it cause or authorize any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly or indirectly, any Intrexon IP with respect to the Reverted Products. NewCo shall immediately discontinue making any representation regarding
its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products. 
 (d) Intrexon Materials. NewCo
shall promptly return, or at Intrexon’s request, destroy, any Intrexon Materials in NewCo’s possession or control at the time of termination other than any Intrexon Materials necessary for the continued development, regulatory approval,
use, manufacture and Commercialization of the Retained Products in the Field. 
 (e) Licenses to Intrexon. NewCo is automatically
deemed to grant to Intrexon a worldwide, fully paid, royalty-free, exclusive (even as to NewCo and its Affiliates), irrevocable, license (with full rights to sublicense) under the NewCo Termination IP, to make, have made, import, use, offer for sale
and sell Reverted Products and to use the Intrexon Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by NewCo in Reverted Products pursuant to Section 10.4(c). The Parties
shall also take such actions and execute such other instruments and documents as may be reasonably necessary to document such license to Intrexon. 

(f) Regulatory Filings. NewCo shall promptly assign to Intrexon, and will provide full copies of, all regulatory approvals and
regulatory filings that relate specifically and solely to Reverted Products. NewCo shall also take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights thereunder to
Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted Products and other products, NewCo shall provide copies of the portions of such regulatory filings that relate to Reverted Products
and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect to the Reverted Products. 

(g) Data Disclosure. NewCo shall provide to Intrexon copies of the relevant portions of all material reports and data, including
regulatory trial data and reports, obtained or generated by or on behalf of NewCo or its Affiliates to the extent that they relate to Reverted Products, within sixty (60) days of such termination unless otherwise agreed, and Intrexon shall have
the right to use any such Information in developing and Commercializing Reverted Products and to license any Third Parties to do so. 

  
 31 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (h) Third Party Licenses. At Intrexon’s written request, NewCo shall promptly
provide to Intrexon copies of all Third Party agreements under which NewCo or its Affiliates obtained a license under Patents claiming inventions or know-how specific to or used or incorporated into the development, manufacture and/or
Commercialization of the Reverted Products. At Intrexon’s written request such that Intrexon may Commercialize the Reverted Products, NewCo shall promptly work with Intrexon to either, as appropriate (i) assign to Intrexon the Third Party
agreement(s), or (ii) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned Third
Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so
notify NewCo and NewCo shall not make such assignment or grant such sublicense (or cause it to be made or granted). 
 (i) Remaining
Materials. At the request of Intrexon, NewCo shall transfer to Intrexon all quantities of Reverted Product (including final products or work-in-process) in the possession of NewCo or its Affiliates. NewCo shall transfer to Intrexon all such
quantities of Reverted Products without charge, except that Intrexon shall pay the reasonable costs of processing and shipping. 
 (j)
Third Party Vendors. At Intrexon’s request, NewCo shall promptly provide to Intrexon copies of all agreements between NewCo or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply, sale, or
distribution of Reverted Products in the Territory. At Intrexon’s request, NewCo shall promptly: (i) with respect to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately
assign (or cause to be assigned), such agreements to Intrexon, and (ii) with respect to all other such Third Party agreements, NewCo shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. NewCo shall be
liable for any costs associated with assigning a Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon, to the extent such costs are directly related to NewCo’s breach. For the avoidance of doubt,
Intrexon shall have no obligation to assume any of NewCo’s obligations under any Third Party agreement. 
 (k)
Commercialization. Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to NewCo, to take any such actions in connection with such
activities as Intrexon (or its designee), at its discretion, deems appropriate. 

  
 32 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 (l) Confidential Information. Each Party shall promptly return, or at the other
Party’s request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination; provided, however, that each Party shall be permitted to retain (i) a single copy of each item
of Confidential Information of the other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii) Confidential Information of the other Party that is maintained as archive copies
on the recipient Party’s disaster recovery and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s rights in Retained Products (in the case of NewCo) or
Reverted Products (in the case of Intrexon). The recipient of Confidential Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information retained in accordance with this
Section 10.4(l). 
 10.5 Surviving Obligations. Termination or expiration of this Agreement shall not affect any rights of
either Party arising out of any event or occurrence prior to termination, including, without limitation, any obligation of NewCo to pay any amount which became due and payable under the terms and conditions of this Agreement prior to expiration or
such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement: Sections 3.1 (as applicable with respect to 10.4(b), 6.1, 6.2 (with subsection (c) surviving only to the extent relating to
Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or Commercialized at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and any relevant definitions in
Article 1. Further, Article 5, Article 7 and Sections 4.4 and 9.5 will survive termination of this Agreement to the extent there are applicable Retained Products. 

ARTICLE 11 

DISPUTE RESOLUTION 

11.1 Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this
Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this Agreement
(other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach, of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of
either Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is
not resolved within thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For the avoidance of doubt, any disputes, controversies or differences arising from a
Committee pursuant to Article 2 shall be resolved solely in accordance with Section 2.4. 

  
 33 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 11.2 Arbitration. Any dispute, controversy, difference or claim which may arise
between the Parties and not from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of or relating to the validity, construction, interpretation, enforceability, breach,
performance, application or termination of this Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Sections 11.9 and 11.10, be settled by binding “baseball arbitration” as follows. Either Party, following the
end of the thirty (30) day period referenced in Section 11.1, may refer such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in the state where the other Party’s
principal office is located (or some other place as may be mutually agreed by the Parties). Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator to resolve the issue, which
arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates, shall have significant experience and expertise in licensing and partnering agreements in the energy and biotechnology industries, and shall have
some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator
meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is
selected (in the case of the three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party a detailed written proposal setting forth its proposed terms for the resolution for the
matter at issue (the “Proposed Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will also provide the arbitrator(s) a copy of this Agreement, as it may be amended at
such time. Within fifteen (15) days after receipt of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the other Party) a response to the other Party’s Support
Memorandum. Neither Party may have any other communications (either written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in this Section 11.2; provided that, the
arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s
appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The
decision of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both
Proposed Terms or award any other relief or take any other action. 
 11.3 Governing Law. This Agreement shall be governed by and
construed under the substantive laws of the State of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 11.4 Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set forth above under
Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs, fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party.
Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, 

  
 34 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 
and agrees that, subject to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final award in any United States District Court located in New
York and that other courts may award full faith and credit to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach of the Agreement, and from the date of the award until paid
in full, at a rate fixed by the arbitrator(s). With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s) or any court or any other forum to award consequential, incidental, special, punitive or exemplary
damages. By entering into this agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages. The only damages recoverable under this Agreement are direct compensatory damages.

 11.5 Costs. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees and expenses against
the Party losing the arbitration. 
 11.6 Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking
equitable relief or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, concerning a dispute either prior to or during any
arbitration if necessary to protect the interests of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties agree that a material breach by either Party of its obligations in Section 3.5 or
Article 7 of this Agreement may cause irreparable harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise available at law, including, without limitation, the recovery of
damages for breach of this Agreement, upon an adequate showing of material breach of such Section 3.5 or Article 7, and without further proof of irreparable harm other than this acknowledgement, such non-breaching Party shall be entitled to
seek (a) immediate equitable relief, specifically including, but not limited to, both interim and permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as the court may deem proper
under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2. 

11.7 Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate protective orders
to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without prior
written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or as
otherwise required by applicable law. 
 11.8 Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be
enforceable after termination of this Agreement for any reason. 

  
 35 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 11.9 Jurisdiction. For the purposes of this Article 11, the Parties acknowledge their
diversity and agree to accept the jurisdiction of any United States District Court located in New York for the purposes of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this
Article 11 and agree not to commence any action, suit or proceeding related thereto except in such courts. 
 11.10 Patent Disputes.
Notwithstanding any other provisions of this Article 11, and subject to the provisions of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon Patents shall be submitted
to a court of competent jurisdiction in the country in which such Patent was filed or granted. 
 ARTICLE 12 

GENERAL PROVISIONS 

12.1 Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any manner the name of the other
or any other trade name or trademark of the other in connection with the performance of this Agreement, except that either Party may use the name of the other Party as required by law or regulation and in press releases accompanying quarterly and
annual earnings reports approved by the issuer’s Board of Directors. 
 12.2 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE
LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING,
NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7. 

12.3 Independent Parties. The Parties are not employees or legal representatives of the other Party for any purpose. Neither Party
shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization of any kind.


  
 36 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 12.4 Notice. All notices, including notices of address change, required or permitted
to be given under this Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the
other party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested. All
such communications shall be sent to the address or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing): 

 

			
	 If to Intrexon:
	  	 Intrexon Corporation
 201 Industrial Road,
#420
 San Carlos, CA 94070
 Attention: President, Energy
Sector
 Fax: (650) 597-4001

		
	 with a copy to:
	  	 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Legal Department

Fax: (301) 556-9902

		
	 If to NewCo:
	  	 Intrexon Energy Partners, LLC
 1750 Kraft Drive,
Suite 1400
 Blacksburg, VA 24060
 Attention: Rick Sterling,
Manager
 Fax: (540) 961-0925

		
	 with a copy to:
	  	 Intrexon Corporation
 20374 Seneca Meadows
Parkway
 Germantown, MD 20876
 Attention: Legal Department

Fax: (301) 556-9902


 12.5 Severability. In the event any provision of this Agreement is held to be invalid or unenforceable,
the valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect. 
 12.6
Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute a waiver of any other or subsequent breach. 

12.7 Entire Agreement; Amendment. This Agreement, including any exhibits attached hereto, constitutes the entire, final, complete and
exclusive agreement between the Parties and supersede all previous agreements or representations, written or oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties). All
information of Intrexon or NewCo to be kept confidential by the other Party under any prior confidentiality agreement, as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth in
Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative of each Party. 

  
 37 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 12.8 Non-assignability; Binding on Successors. Any attempted assignment of the rights
or delegation of the obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party; provided, however, that either Party may assign its rights or delegate its obligations under this
Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale of all or
substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the assignor’s obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors,
executors, heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation,
corporate reorganization, or similar transaction, or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed by such successor in interest or its affiliate by operation of law (e.g., in the context
of a reverse triangular merger)), the intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement shall be automatically excluded from the rights licensed to the other Party under
this Agreement. 
 12.9 Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its obligations
under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes,
governmental regulation, fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay promptly notifies the other Party of the delay. 

12.10 No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual property, whether by
implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement. 
 12.11 Legal Compliance. The
Parties shall review in good faith and cooperate in taking such actions to ensure compliance of this Agreement with all applicable laws. 

12.12 Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF, or other means of
electronic communication), each of which taken together will constitute one and the same instrument, and any of the Parties hereto may execute this Agreement by signing any such counterpart. 

12.13 Relationship of Parties. It is the intent of the parties hereto that the actions to be taken by NewCo hereunder shall be those of
an independent contractor non-agent maintaining an ‘arms-length transaction’ between the parties, and no term or provision of this Agreement shall be construed as creating an agent, servant, employee, or representative relationship between
NewCo and Intrexon. Notwithstanding any other provision of this Agreement to the contrary, the parties understand and agree that their relationship hereunder is not one of partnership, association, trust, joint venture or entity of any kind. 

[Remainder of page intentionally left blank.] 

  
 38 









 Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment
under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the Parties hereto
have duly executed this Exclusive Channel Collaboration Agreement. 
  

									
	INTREXON CORPORATION	 		 	INTREXON ENERGY PARTNERS, LLC
					
	By:	 	/s/ Donald P. Lehr	 		 	By:	 	/s/ Rick Sterling
	Name:	 	Donald P. Lehr	 		 	Name:	 	Rick Sterling
	Title:	 	Chief Legal Officer	 		 	Title:	 	Manager

 SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION AGREEMENT 

  
 39